Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

Author：  

Publisher： Adis International

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.27, Iss.9, 2011-09, pp. : 14-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments

By Leitch Heather A.  

Drugs, Vol. 71, Iss. 2, 2011-01 ,pp. : 155-177

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic Considerations in Treating Iron Overload in Patients with β-Thalassaemia, Sickle Cell Disease and Myelodysplastic Syndromes in the US: A Literature Review

By Zhang Bin  

PharmacoEconomics, Vol. 29, Iss. 6, 2011-06 ,pp. : 461-474

Adis International

Access to resources Recommend Favorite

Myelodysplastic Syndromes: Iron Overload Consequences and Current Chelating Therapies

By Greenberg Peter L.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 91-96

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Immunosuppressive Therapy for Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3184-3189

Bentham Science Publishers

Access to resources Recommend Favorite

Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload

By  

Current Pharmaceutical Design, Vol. 12, Iss. 16, 2006-06 ,pp. : 1943-1947

Bentham Science Publishers

Access to resources Recommend Favorite